We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

115 hedge funds and large institutions have $208M invested in Lineage Cell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

65% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 20

59% more call options, than puts

Call options by funds: $818K | Put options by funds: $514K

47% more capital invested

Capital invested by funds: $142M → $208M (+$66.6M)

13% more funds holding

Funds holding: 102 → 115 (+13)

7.8% more ownership

Funds ownership: 37.32% → 45.12% (+7.8%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
115
Holders Change
+13
Holders Change %
+12.75%
% of All Funds
2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
34
Reduced
15
Closed
20
Calls
$818K
Puts
$514K
Net Calls
+$304K
Net Calls Change
+$492K

Top Buyers

1
BlackRock
BlackRock
New York
+$15.7M
2
JP Morgan Chase
JP Morgan Chase
New York
+$5.05M
3
State Street
State Street
Massachusetts
+$4.66M
4
Northern Trust
Northern Trust
Illinois
+$3.45M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.78M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$3.35M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.4M
3
ECM
ExodusPoint Capital Management
New York
-$785K
4
HF
HRT Financial
New York
-$679K
5
Goldman Sachs
Goldman Sachs
New York
-$479K
Name Holding Trade Value Shares
Change 		Change in
Stake
LI
76
Lafayette Investments
Maryland
$37K – – –
OFG
77
Oxford Financial Group
Indiana
$36K – – –
PSB
78
Piscataqua Savings Bank
New Hampshire
$35K – – –
Citigroup
79
Citigroup
New York
$33K +$9.13K +3,527 +43%
RAM
80
Riggs Asset Management
Pennsylvania
$30K – – –
Wells Fargo
81
Wells Fargo
California
$30K +$2.35K +910 +9%
QPWM
82
Quadrant Private Wealth Management
Pennsylvania
$29K – – –
Legal & General Group
83
Legal & General Group
United Kingdom
$28K +$25K +9,674 New
AIP
84
Ameritas Investment Partners
Nebraska
$27K +$24.6K +9,508 New
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
$26K +$11.6K +4,475 +97%
PCM
86
Pinz Capital Management
New York
$26K +$23.5K +9,100 New
TRCT
87
Tower Research Capital (TRC)
New York
$25K +$21.8K +8,415 +4,208%
FCMT
88
Founders Capital Management (Texas)
Texas
$14K – – –
AF
89
Allworth Financial
California
$14K +$12.3K +4,750 New
Osaic Holdings
90
Osaic Holdings
Arizona
$13K -$8.08K -3,123 -53%
UBS Group
91
UBS Group
Switzerland
$13K -$7.22K -2,791 -38%
IA
92
IFP Advisors
Florida
$9K – – –
AFG
93
Albion Financial Group
Utah
$9K +$7.87K +3,043 New
CQS
94
Credential Qtrade Securities
$8.29K – – –
PP
95
Pacifica Partners
Canada
$8K – – –
RFA
96
Reilly Financial Advisors
California
$6K – – –
First Manhattan
97
First Manhattan
New York
$5K +$5.17K +2,000 +2,128%
CWP
98
Concord Wealth Partners
Virginia
$4K – – –
Fifth Third Bancorp
99
Fifth Third Bancorp
Ohio
$4K – – –
AIC
100
Archer Investment Corporation
Indiana
$2.85K – – –
2 3
4
5 6

LCTX Hedge Fund Activity: Q2 2021 in Review

115 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2021, worth a combined $208M — up 47% from $142M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new LCTX positions and 20 closed out — a net gain of 13 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, exiting entirely with an estimated $3.35M sold.

  • 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2021, up from 102 in Q1 2021.
  • Funds reported $208M of Lineage Cell Therapeutics stock for Q2 2021, up 47% quarter-over-quarter.
  • 33 funds opened new Lineage Cell Therapeutics positions in Q2 2021 and 20 closed out, a net change of +13 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2021 was BlackRock, an estimated $15.7M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2021 was Millennium Management, an estimated $3.35M sold.

Based on aggregated 13F filings for Q2 2021.